Safety Strategy for Cephalon Pain Drugs Receives FDA Approval

According to a Cephalon news release, the FDA has approved a risk evaluation and mitigation strategy for Cephalon’s Fentora and Actiq drugs to manage breakthrough pain in opioid-tolerant patients with cancer.

Advertisement

Click here to read the Becker’s ASC Review coverage on Cephalon Fentora and Actig drugs.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.